Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9944241 | 0.89 | MAPT (0.51) | MAPTKMT2AMEN1MAPK14RAB9A | |
| SCHEMBL9944337 | 0.88 | MAPT (0.60) | MAPTKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL1459379 | 0.88 | MAPT (0.53) | MAPTKMT2AMEN1MAPK14RAB9A | |
| SCHEMBL1457774 | 0.83 | MEN1 (0.62) | MAPTKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL9944240 | 0.83 | MAPT (0.58) | MAPTKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL2917616 | 0.78 | FKBP5 (0.73) | MAPTKMT2AMEN1FKBP5RAB9A | |
| SCHEMBL9944189 | 0.73 | MAPT (0.54) | MAPTKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL823156 | 0.73 | RAB9A (0.75) | MAPTKMT2AMEN1FKBP5RAB9A | |
| SCHEMBL1458178 | 0.73 | MAPT (0.56) | MAPTKMT2AMEN1RAB9ANPC1 | |
| SCHEMBL19799106 | 0.73 | TP53 (0.54) | MAPTKMT2AMEN1MAPK14RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | KING'S COLLEGE LONDON (GB) | 2012-06-14 | — | — | US | disclosed |
| WO-2011027106-A1 | THERAPEUTIC ARYL-AM I DO-ARYL COMPOUNDS AND THEIR USE | KING'S COLLEGE LONDON (GB) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149737-A1 | Therapeutic Aryl-Amido-Aryl Compounds and Their Use | RARA, RARB, RARG | MAPT 150/4885KMT2A 1418/4885MEN1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.